New article about Alzinova published by BioStock! 

Date: 2023-04-24

Alzinova is currently in the subscription period for warrants of series TO3. Alzinova has already secured subscription commitments of approximately SEK 7.5 million from members of the company's board, management team, and founders.

CEO Kristina Torfgård shares updates on the latest clinical progress and how the proceeds from the issue will be used.

Read the article (in Swedish)